💦 Topical Glycopyrronium (Qbrexza) Simulator

Applying the Glycopyrronium Wipe to the Underarm

A single-use cloth delivers glycopyrronium solution directly onto skin.

• 2.4%: Dose per wipe (glycopyrronium cloth)
• Axilla: Application site (underarm skin)
• ~1h: Onset window (placeholder estimate)
• Daily: Frequency (once per day typical)

Wipe mechanics

Cloth transfers drug onto stratum corneum for absorption.

Blocking Muscarinic M3 Receptors on Sweat Glands

Glycopyrronium competitively binds M3 receptors on gland cells.

• M3: Receptor type (muscarinic subtype)
• Competitive: Binding mode (vs acetylcholine)
• Local: Selectivity (skin-limited target)
• ~2-4h: Peak binding (placeholder estimate)

Receptor pharmacology

Drug occupies receptor site, preventing ACh docking.

Interrupting the Local Acetylcholine Signal

Nerve-released acetylcholine can no longer activate blocked receptors.

• ACh: Neurotransmitter (acetylcholine)
• Sympathetic cholinergic: Pathway (innervates eccrine glands)
• Blocked: Signal outcome (no secretory trigger)
• ~24h: Duration (per application)

Signal pathway

Blocked receptor halts downstream secretory activation.

Reduced Sweat Gland Output at the Treated Site

Eccrine glands secrete less sweat once receptors stay blocked.

• ~30-50%: Sweat reduction (placeholder trial figure)
• Gravimetric: Measure (sweat weight test)
• Hours: Onset (gradual decline)
• ~1 day: Duration (per wipe use)

Output measurement

Sweat output declines as blockade level rises.

Localized and Systemic Anticholinergic Effects

Some drug reaches circulation, causing mild anticholinergic effects.

• Dry mouth: Common effect (most frequent report)
• Mydriasis risk: Eye effect (if contact occurs)
• Frequency: Risk driver (more uses raise risk)
• Mostly mild: Severity (placeholder summary)

Safety monitoring

Frequent use raises systemic anticholinergic exposure.

Higher weekly frequency increases side effect risk in this model.